History of Present Illness
The patient presented to the emergency room complaining of increased joint swelling and stiffness in her hands, shoulders, elbows, and knees. She stated that these symptoms were worse in the morning and improved with activity throughout the day. She stated that her joints were not painful per se. She also indicated that she noticed increasing weakness in her arms and legs over the preceding few weeks. She denied any history of recent fevers or illnesses. She had been taking hydroxychloroquine for lupus, but stopped taking it 4 months prior to presentation. She had not seen a doctor in 8 months.
Past Medical History
Systemic lupus erythematosus (SLE) diagnosed 2 years prior to presentation and a history of gastroesophageal reflux disease (GERD).
Past Surgical History
None.
Drug History
Family/Social history
The patient has a cousin diagnosed with SLE. Her father died of congestive heart failure at age 68 years, her mother of a myocardial infarction at age 63 years. She has brothers with diabetes and hypertension. The patient drinks socially, but denied any history of tobacco or drug abuse.
Physical Examination
Vital signs: temperature, 37.3ºC; pulse, 82 beats per minute; respiratory rate, 16 breaths per minute; blood pressure (systolic/diastolic), 114/75 mmHg. The patient appeared well nourished and was in no acute distress. Cardiac exam detected a systolic ejection murmur, loudest at the left sternal border. There was swelling and decreased range of motion in multiple joints, including the wrists, elbows, shoulders, hands, and knees. The elbow joints were warm to the touch. The skin over the fingers was hard (sclerodactyly) and tight, causing abnormal curvature of the fingers. There was a mild, maculopapular rash with excoriation over the chest and abdomen. Neurologic exam was significant for decreased strength in shoulder and hip flexion and extension.
Principal Laboratory Results
( Table 1) .
Results of Additional Diagnostic Procedures and Tests
Her electrocardiogram (ECG) showed normal sinus rhythm with no evidence of acute cardiac pathology. Chest x-ray showed an enlarged heart and a reticulonodular infiltrate in the lower lobes of both lungs. Chest computed tomography (CT) scan further delineated these lesions as patchy ground-glass and faint centrilobular lobules in the posterior lower lobes bilaterally. The CT scan also showed an enlarged pulmonary artery. Echocardiography confirmed cardiomegaly and revealed evidence of pulmonary hypertension. Pulmonary function tests (PFTs) were abnormal and indicative of restrictive lung disease.
labmedicine.com inflammatory connective tissue disease. Muscle weakness. The consistency of her symptoms of lower and upper extremity weakness suggests either a neurologic or muscular origin. The muscular etiology is favored by laboratory data showing elevated serum and urine levels of several enzymes (eg, CK, AST, ALT, and LD) and substances found in skeletal and other types of muscle or released into the serum (eg, uric acid) or urine (eg, myoglobin) following the breakdown of muscle tissue (see below). Sclerodactyly. This term is used to describe changes in the skin of the fingers. Initially, there is swelling that develops over time into dermal fibrosis and skin atrophy, making the fingers tight and contracted. This finding is characteristic of localized scleroderma. Pulmonary findings. This patient's radiographic and PFT findings are consistent with a restrictive lung disease. These disorders are characterized by diffuse and chronic inflammation of pulmonary connective tissue leading to reduced lung expansion and decreased total lung capacity. The most common causes of these findings include environmental exposures (eg, asbestos), drug-induced pulmonary fibrosis, idiopathic pulmonary fibrosis, and inflammatory connective tissue diseases. Cardiac abnormalities. The initial indication of cardiac disease in this patient was the finding of cardiomegaly on radiographic studies. An echocardiogram revealed evidence of pulmonary hypertension (ie, elevated blood pressure in the pulmonary arteries). This may be the source of the heart murmur detected on physical exam. Pulmonary hypertension can be idiopathic or caused by chronic lung disease, valvular heart disease, or recurrent thromboembolic disease. Chronic restrictive lung disease compounded by an inflammatory connective tissue disease is a likely cause of pulmonary hypertension and consequent right-sided cardiac muscle hypertrophy. Abnormal laboratory findings. Increased levels of enzymes (ie, CK, CK-MB, cTnI, AST, ALT, LD) and substances released into the serum (uric acid) or urine (myoglobin) when muscle cells undergo necrosis, suggest that the patient's muscle weakness could have been caused by the increased breakdown of muscle tissue. Her positive ANA titer, speckled ANA pattern, positive dsDNA antibody titer, and positive U1-RNP ENA screen are consistent with a connective tissue disease.
Most likely diagnosis: mixed connective tissue disease (MCTD).
MCTD was defined by Sharp 1 in 1972, as a syndrome with overlapping symptoms of SLE, systemic sclerosis, and polymyositis. However, there is considerable debate about whether or not MCTD is an independent pathologic entity. 2 Mixed connective tissue disease is associated with high titers of antibodies to U1-RNP, a 68-kilodalton (kD) constituent of nuclear ribonucleoproteins (RNPs).
4.
There are several different diagnostic algorithms that include criteria for the diagnosis of MCTD. Two of these algorithms appear to be the most diagnostically sensitive ( Table  2) . 3, 4 Both include the criterion of a positive U1-RNP screen (ie, the presence of serum antibodies to the U1-RNP ENA)-the defining feature of this disease. Our patient was positive for these antibodies by enzymeimmunoassay (EIA), and her ANA titer (>1:2560) met the minimum cutoff value for ANA titer required by the algorithm of Kahn and Appelboom 4 for the diagnosis of MCTD. Additional criteria required by these algorithms for the diagnosis of MCTD, include some combination of Raynaud's phenomenon, swollen hands and/or fingers, synovitis, and myositis. The criteria of Alarcon-Segovia and Villareal 3 add acrosclerosis (hardening of the bones of the face and fingers) to the aforementioned list of clinical signs and symptoms. Our patient had no history of Raynaud's phenomenon or acrosclerosis, but she did have a history of joint pain, swelling, and stiffness, as well as physical evidence of swelling and stiffness on this admission, consistent with synovitis. She had sclerodactyly, the clinical consequence of chronic inflammation and swelling of the fingers, and a defining symptom of limited systemic sclerosis. She also had abundant evidence of myositis, including neurologic examination findings consistent with proximal muscle weakness -the pattern seen typically in patients with inflammatory myopathiesand abnormal laboratory test findings consistent with increased breakdown of muscle tissue, including increased serum levels of the muscle-derived enzymes, CK, AST, ALT, LD, and the muscle breakdown product, uric acid, coupled with an increased urine concentration of the muscle breakdown product, myoglobin. Thus, our patient meets the criteria used in the algorithms of Alarcon-Segovia and Villareal 3 and of Kahn and Appelboom 4 for the diagnosis of MCTD ( Table 2) .
5.
Anti-nuclear antibodies (ANAs) are autoantibodies against certain nuclear antigens that can occur in the serum of patients with various rheumatic diseases. The presence of ANAs in serum can be determined by different methods, including indirect immunoflourescence assay (IFA). The IFA test provides information on whether or not the patient's serum contains ANAs at a clinically significant level and if so, the nature of the nuclear staining pattern caused by a specific patient's ANAs. Using the IFA method, a patient's serum is incubated with cells, usually from a human tumor cell line. If the patient's serum contains autoantibodies against nuclear antigens, they will bind to these antigens in the nucleus of the human tumor cells and form an antigen-antibody complex. The presence of these complexes is detected by adding anti-human IgG antibodies linked to molecules of a substance [eg, fluorescein isothiocyanate (FITC)] capable of fluorescence when exposed to the appropriate wavelength of light energy. If ANAs are present in the patient's serum and bound to the tumor cell nuclear antigens, addition of the fluorescently labeled anti-human IgG antibodies will cause the formation of a (nuclear antigen)-(ANA)-(anti-human antibody-fluorescent label) complex in these cells. Subsequent exposure of these cells to the appropriate wavelength of UV light will cause the fluorescent label to emit light of a characteristic wavelength that can be observed using a fluorescent microscope. If the test is positive, the patient's serum is diluted and re-tested to determine the highest dilution that still yields a positive ANA test. Patients whose serum contains a high concentration of ANAs will require higher and higher dilutions before the highest dilution still yielding a positive ANA test is found. Because positive ANA tests can be obtained using serum from healthy individuals, a positive ANA must be interpreted carefully. It is estimated that the serum from 20% to 30% of all individuals contains ANAs that will yield a titer of >1:40. 5 Moreover, falsepositive ANA tests are particularly common among females and older individuals. For these reasons, it is important to establish an appropriate reference titer above which results are likely to be clinically significant. An ANA titer of >1:160 is regarded generally as clinically significant. However, because no autoimmune disease can, or should, be diagnosed on the basis of a positive ANA test alone, 5 it is important that a positive ANA test be interpreted in conjunction with the patient's history and clinical and other laboratory findings. The specific fluorescent staining pattern of the patient's ANAs is determined by viewing the human tumor cells used in the ANA test using a fluorescent microscope. Several characteristic ANA staining patterns have been described (eg, speckled, diffuse, peripheral, nucleolar, centromeric). However, these patterns are not specific for a single disease entity (ie, the same, or a similar, pattern can be seen in more than one disease) (Note: For a more thorough discussion of ANA staining patterns and their clinical significance, see
Greidinger EL, Hoffman RW. Antinuclear antibody testing: Methods, indications, and interpretation. Lab Med. 2003;34:113-117). Therefore, it is important that a positive ANA test be followed up by additional testing to define the specific type of ANAs (ie, the antigen(s) against which the patient's autoantibodies are directed) present in the serum of a patient with a positive ANA test. Examples of specific antigens against which ANAs can be directed include double-stranded DNA (dsDNA) and various extractable nuclear antigens (ENAs) ( Table 1) . The specific autoantibodies seen in our patient were anti-dsDNA and anti-(U1-RNP). As indicated previously, the presence of anti-(U1-RNP) antibodies in a patient's serum is among the diagnostic criteria for MCTD; however, they can also be found in the serum of patients with SLE. Anti-dsDNA antibodies are found almost exclusively in the serum from patients with SLE; however, they can be found, albeit at low titer, in the serum of patients with MCTD. 1 On the other hand, while the presence of anti-Sm antibodies is a hallmark of the serum from patients with SLE, these antibodies are not found typically in the serum from patients with MCTD. 1 The constellation of these laboratory findings [ie, positive ANA, dsDNA (low titer), U1-RNP antibody tests, and negative anti-Sm antibody test], when coupled with our patient's clinical and other diagnostic findings, provide strong evidence for the diagnosis of MCTD.
6.
No. As discussed previously, elevations of CK, AST, ALT, and LD occur commonly in the serum from patients with inflammatory muscle disorders, including polymyositis, dermatomyositis, and MCTD. However, the magnitude of the increase in CK-MB and cTnI in our patient's serum is unusual for a patient with MCTD. CK-MB is considered a marker of cardiac muscle damage when the CK index is greater than 3 (no units). However, CK-MB levels are often high in serum from patients with inflammatory myopathies, because the regenerating muscle in these conditions makes a significant amount of the MB isoform of CK. 6 Consequently, CK-MB is not a reliable marker of cardiac injury in such conditions. Cardiac troponin I (cTnI) is specific for cardiac muscle injury and usually is not elevated as a consequence of the skeletal muscle damage that occurs in patients with inflammatory myopathies. 7 Our patient had a normal ECG, no clinical signs or symptoms of an acute coronary syndrome, a marginally increased CK index, and only a relatively modest increase in cTnI concentration compared to the magnitude of the increase in cTnI concentration (ie, >1.5 ng/mL) that occurs typically in patients with an acute coronary syndrome. These findings suggest that there may be some ongoing sub-acute or chronic myocardial process occurring in our patient. Myocarditis is a known complication of MCTD. 6, 8 In some cases, myocardial inflammation may be a primary autoimmune phenomenon. In fact, circulating anti-myocardial antibodies have been detected in serum from some patients with MCTD; however, this finding does not correlate with clinically evident cardiac disease. 9 Myocardial inflammation has also been attributed to the secondary effects of pulmonary hypertension and cardiomegaly. 8 Both pulmonary hypertension and cardiomegaly were present in our patient.
7.
Our patient's restrictive pulmonary disease and pulmonary hypertension are significant in the context of the diagnosis of MCTD because it has been reported that 85% of patients with MCTD demonstrate some evidence of pulmonary disease 8 and pulmonary hypertension appears to be a common feature of MCTD. 10 Pulmonary symptoms in affected individuals can include dyspnea, chest pain, and cough. However, similar to our patient, 73% of patients with MCTD are asymptomatic for these particular pulmonary symptoms. Moreover, in patients with MCTD, PFTs commonly show a restrictive pattern with decreased vital capacity (VC) and reduced carbon monoxide diffusion capacity (DLCO). Pulmonary hypertension can be caused by chronic interstitial lung disease associated with a number of different conditions. However, in patients with MCTD there appears to be an additional primary defect in the pulmonary vasculature. Pulmonary arterioles show intimal proliferation and medial hypertrophy, which are independent of the effects of pulmonary fibrosis. 7 Other features of our patient's disease commonly occur in patients with MCTD, including leukopenia and GERD. Leukopenia, particularly in the lymphocyte lineage, is found in 50% to 75% of patients with MCTD. 1, 8 The degree of leukopenia is thought to correlate with disease activity. Our patient was leukopenic (Table 1) , with a low percentage of lymphocytes on the differential cell count (17%). In addition, esophageal disturbances are known to occur in both patients with scleroderma and MCTD. 9 Thus, our patient's GERD may be an additional consequence of her MCTD. Lastly, the cardiac, pulmonary, and gastrointestinal manifestations of MCTD may cluster together. Lash 9 reported 5 cases of MCTD with myocarditis. Each of these patients also had pulmonary fibrosis and esophageal dysmotility. This clustering may indicate an interaction between systems, (ie, pulmonary disease leads to pulmonary hypertension, and myocardial damage). Alternatively, it may just reflect multisystem involvement correlating with more severe MCTD.
8.
As in most collagen vascular diseases, MCTD is treated with immunosuppression drug therapy. 8 Glucocorticoids are used initially, but may be supplemented with stronger immunosuppressant agents. Anti-malarial drugs or methotrexate can be used in patients susceptible to severe glucocorticoid-related side effects. Pulmonary hypertension requires treatment with calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, or intravenous administration of prostacyclin. In patients with MCTD who respond well to steroid therapy, the prognosis is good. 8 Patients with MCTD and pulmonary and cardiac complications, however, do more poorly. 8, 9 Pulmonary hypertension, like that seen in our patient, is the most common cause of death in patients with MCTD. LM Keywords mixed connective tissue disease, antinuclear antibodies, restrictive lung disease, pulmonary hypertension.
